Biodexa Pharmaceuticals PLC shareholders approved a share capital reorganization that alters the company’s American Depositary Share (ADS) structure while maintaining proportional ownership for investors. The clinical-stage biopharmaceutical company announced on July 29, 2026, that all four resolutions proposed at its General Meeting were passed, enabling the adjustment of its share count and granting directors authority to issue new shares on a non-pre-emptive basis.

The primary operational impact of the vote is the change in the ADS ratio, which will shift from 500,000 ordinary shares per ADS to 50 ordinary shares per ADS. This adjustment takes effect at 08.00 BST (03.00 EDT) on July 30, 2026. Biodexa clarified that this is not a reverse stock split; rather, it is a reorganization that reduces the number of ordinary shares outstanding by a factor of 10,000 while keeping the nominal value of £0.000001 per share constant. Consequently, the total number of ADSs outstanding remains identical to the pre-reorganization count.

Following the implementation of the reorganization, Biodexa will have 51,453,281 ordinary shares of £0.000001 each outstanding. This figure corresponds to 1,029,063 ADSs, which matches the number of ADSs in circulation prior to the change. The company emphasized that the proportional ownership of holders of ordinary shares and/or ADSs will not change, except where fractional entitlements are treated as specified in the Notice of Meeting.

In addition to the structural changes, the Board secured authority through resolutions 2 and 3 to allot ordinary shares on a non-pre-emptive basis. This power allows the directors to issue new equity without offering pre-emptive rights to existing shareholders, providing flexibility for future capital raises or strategic transactions without requiring immediate further shareholder approval for each issuance.

Share Capital Structure Post-Reorganization

The full text of the resolutions passed can be accessed via the Notice of the General Meeting on Biodexa’s website. The company continues to develop its pipeline of innovative products, including eRapa for gastrointestinal cancers, MTX240 for Gastrointestinal Stromal Tumors, and tolimidone for type 1 diabetes, headquartered in Cardiff, UK.

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) held its first round table meeting in Paris, France, on July 28, 2026, to expand support for patients with Familial Adenomatous Polyposis (FAP) and their prescribers. The clinical-stage biopharmaceutical company stated that this engagement aims to improve outcomes and quality of life by facilitating the sharing of experience and expertise among patients, advocacy groups, and clinicians. This strategic step augments Biodexa’s previous initiative of making its investigational medicine, eRapa, available for FAP patients via an Early Access Program and Named Patient prescribing.

Stephen Stamp, Chief Executive Officer of Biodexa, said the company is committed to improving the lives of patients and supporting clinicians who treat individuals with no currently approved therapeutic options. The round table activities are designed to complement the availability of eRapa, ensuring that prescribers have both the medicinal tool and a community-supported knowledge base necessary for effective patient management.

Strategic Support for FAP Patients

Biodexa’s approach integrates multiple support mechanisms to assist both patients and healthcare providers. The company is leveraging insights from these collaborative sessions to refine its support structures. The key components of this expanded support framework include:

The sharing of experience among stakeholders is informing Biodexa’s goal of improving outcomes. These activities complement the availability of eRapa, ensuring that prescribers have both the medicinal tool and the community-supported knowledge base necessary for effective patient management.

What the Numbers Show

While this announcement focuses on operational and patient-support initiatives rather than financial metrics, the expansion of the Early Access Program signals Biodexa’s commitment to real-world evidence generation. The ability to prescribe eRapa outside of clinical trials represents a significant milestone in the drug’s development lifecycle, potentially accelerating data collection on efficacy and safety in a broader patient population. This move may influence future regulatory discussions and commercial strategy for eRapa in treating gastrointestinal conditions such as FAP.